Advanced colon cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Advanced colon cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal. We tested a recently described medical procedure using a thermostable autologous hemoderivative purported to inhibit tumor growth possibly through an immunological mechanism of action.
Patients and Methods
Metastatic colon cancer patients chemotherapy-resistant, high CEA plasma levels, in progression, were 2-group randomized. Group 1 received the test procedure and Group 2 adequate control measures. During an 8-mo follow-up period (n=101), tumor growth, number of cases attaining clinical nonprogressive status, and mortality were assessed monthly. Immunological effect was assessed by delayed-type hypersensitivity test and lymphocyte proliferation assay. Responding-tumors histopathologies were studied.
Results and Discussion
In a significant number of cases, the test procedure promoted inhibition of tumor growth, nonprogressive disease status, and lower cumulative mortality. These clinical results were associated with polyvalent immunization against several tested antigens: the hemoderivative used for treatment, the blood tumor markers, and the regulatory lymphocyte population (CD4+CD25+). Interference with this regulatory activity could explain the selective autoimmunity suggested by the histopathology findings in responding tumors.
The autologous hemoderivative tested is antigenically polyvalent and promotes a polytargeted immune response associated with a tumor antiprogressive effect, consequently, acting as an autologous hemoderivative cancer vaccine.
- Lasalvia E, et al. Autologous induction of tumoral fibrogenesis. Neoplasia 1995; 12:5–10.
- Lasalvia E, Cucchi S, Carlevaro T, Vasquez J, Riotorio R, Fierro L. Anti-metastatic effect of a blood fraction from cancer patients (Meeting abstract). Proceedings 31st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 1995, Abstract No. 730
- Lasalvia-Prisco E, et al. Antitumoral effect of a vaccination procedure with an autologous hemoderivative. Cancer Biol Ther 2003; 2:155–160.
- Berd D, Mastrangelo MJ, Engstrong P, Maguire H. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982; 42:4862–4866.
- Leong SP, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999; 22:166. CrossRef
- Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655.
- Therasse P, et al. New guideline to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Nat Cancer Inst 2000; 92:205–216. CrossRef
- World Medical Association Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and as revised in Tokyo, 1975, in Venice, 1983, in Hong Kong, 1989. Version with changes of 1997.
- PDQ (Physician Data Query) National Cancer Institute, comprehensive cancer database.
- Ozer H, et al. 2000 update of recommendations for the use of heamatopoietic colony-stimulating factors: evidencebased, clinical practice guidelines. J Clin Oncol. 2000; 18:3558–3585.
- Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Vazquez J. Lasalvia-Galante E, Golomar W. Colorectal cancer: comparative effects of an autologous hemoderivative vaccine with a CEA vaccine and/or an autologous [CD4+CD25+] vaccine. Proceedings 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, USA, 2005, Abstract No. 2596.
- Wan Fai Ng, et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 2001; 98:2736–2744. CrossRef
- Gauthier LR, et al. Detection of circulating carcinoma cells by telomerase activity. Br J Cancer 2001; 84:631–635. CrossRef
- National Cancer Institute, US: Common terminology criteria for adverse events v3.0 (CTCAE).
- Saetang T, Suttijitpaisal P, Ratanabanangkoon K. Preparations of toxic components from Naja kaouthia venom by selective heat denaturation. J Nat Toxins 1998; 7:37–44.
- Bruster HTH, Kuntz BME, Scheja JW. Autovaccination plus heat-inactivated autologous plasma in AIDS Patients. Lancet 1988; 1:1284–1285. CrossRef
- Petrunin DD, Lopukin Iu M, Molodenkov MN, Olifirenko GA. Immunochemical identification of thermostable alphaglycoprotein in blood sera in various immune system diseases. Biull Eksp Biol Med 1982; 93:66–68. CrossRef
- Snegotska O. [Autovaccines for the treatment of cancer]. Folia Clin Int (Barc. Spain) 1965; 15:303–308.
- Liyanage UK, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756–2761.
- Advanced colon cancer
Volume 23, Issue 1 , pp 91-104
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Autologous hemoderivative
- colon cancer
- Industry Sectors
- Author Affiliations
- 1. Research & Development Department, PharmaBlood Inc, 2050 NE 163rd Street, 2nd Fl, # 202, 33162, North Miami Beach, Florida, USA
- 2. National Institute of Oncology, (initial data) 8 de Octubre s/n, Montevideo, Uruguay
- 3. Centre De Cancerologie Hartmann, 26, Boulevard Victor-Hugo, 92200, Neuilly Sur Seine, France
- 4. Department of Advanced Medical Treatments, 8 de Octubre 2323, #905, Montevideo, Uruguay